Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter blood thinner course after stents may cut bleeding risk

NCT ID NCT07374718

Disease control Sponsor: Shenyang Northern Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether heart attack patients with high bleeding risk can safely take blood thinners for only one month after a special drug-coated stent, instead of the usual 12 months. About 468 participants will be randomly assigned to the shorter or standard therapy. The goal is to see if the shorter plan reduces bleeding complications without increasing heart attacks or strokes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) followed by P2Y12 inhibitor monotherapy
What this could lead to
If successful, this could lead to a safer, shorter antiplatelet regimen that lowers bleeding risk without increasing heart attacks or strokes in high-risk patients.
What could go wrong
This is an early-stage trial with 468 participants, so results may not apply to all patients. The shorter therapy might not protect against ischemic events as well as standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 468 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥ 18 years old * ACS patients with high bleeding risk (meeting the ARC-HBR criteria) * Moderate-to-high ischemic risk (OPT-CAD score ≥ 90) * Predicted by the investigator to be able to tolerate 12 months of DAPT * Voluntarily participate and sign the informed consent form, and be willing to receive the designated follow-up of this trial at specific time points * Coronary artery lesions are primary and in-situ coronary artery lesions * Target lesion diameter stenosis ≥ 70% or ≥ 50% (visual estimation) accompanied by evidence of myocardial ischemia Exclusion Criteria: * Patients with known allergy or contraindication to P2Y12 inhibitors, aspirin, or contrast agents * Patients planning to undergo surgical intervention within 12 months * Left Ventricular Ejection Fraction (LVEF) \< 35% * Patients with contraindications to PCI * Patients with a history of substance abuse (alcohol, cocaine, heroin, etc.), or with an expected life expectancy of less than 1 year * Subjects with poor compliance or judged by the investigator to be unsuitable for participating in the study * Female patients who are planning to be pregnant or are pregnant/lactating, and male patients planning to impregnate * Chronic total occlusion lesions * Lesions involving the left main coronary artery * Severe calcified and tortuous lesions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome (ACS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome (ACS) Coronary artery disease (CAD) High bleeding risk(HBR)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • General Hospital of Northern Theater Command

    Shenyang, Liaoning, 110000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.